抗体薬物複合体 (ADC) 市場 : 2028年までの世界予測

Report Overview

The global antibody drug conjugates market size is projected to reach USD 19.8 billion by 2028 from USD 9.7 billion in 2023, at a CAGR of 15.2% during the forecast period. Factors such as the rising prevalence of cancer, robust products under clinical studies, and increased industrial collaborations are likely to drive market growth. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.

“The Kadcyla segment held the dominant share in the antibody drug conjugates market.”
Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. The Kadcyla segment accounted for the largest share of the market in 2022.  Extensive use of Kadcyla for breast cancer treatment is likely to drive the growth of
the market. Recent approvals for various disease indications for Polivy and Adcertis are further likely to uplift the market in the coming years.

“Breast cancer segment accounted for the largest share of the disease type segment in 2022.”
Based on disease type, the antibody drug conjugates market is segmented into breast cancer, lung cancer and other diseases. In 2022, the breast cancer segment accounted for the largest share of the antibody drug conjugates market. The segment held the dominant share in the market owing to various factors such as the increasing prevalence of breast cancer coupled with the rising demand for ADCs for breast cancer. The launch of biosimilar is further likely to have a positive impact on the market growth.

“Asia Pacific region is likely to grow at a faster pace.”
The antibody-drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for ADCs in China and Japan. The launch of the biosimilar Ujvira for the treatment of breast cancer in India is likely to give momentum to the market growth in the region.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%, and Demand Side – 20%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd (Switzerland)
• Daiichi Sankyo Company, Limited (Japan)
• Seagen Inc. (US)
• Gilead Sciences, Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US),
• Astellas Pharma Inc (Japan)
• AstraZeneca (UK)
• ADC Therapeutics SA (Switzerland)
• ImmunoGen, Inc. (US)
• Zydus Group (India)
• Abbvie Inc. (US)
• Ambrx (US)
• LegoChem Biosciences, Inc. (South Korea)
• Byondis (Netherlands)
• ProfoundBio (China)
• RemeGen (China)
• Sutro Biopharma, Inc. (US)
• Lepu Biopharma CO., Ltd. (China)
• Zymeworks Inc. (Canada)
• Mersana Therapeutics (US)
• Duality Biologics (China)
• LaNova Medicines (China)
• Exelixis, Inc. (US)
• BiOneCure Therapeutics Inc. (US)
• Tripartite Therapeutics, Inc. (Taiwan).

Research Coverage:
This report provides a detailed picture of the antibody drug conjugates market. It aims to estimate the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall antibody drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:
• Analysis of key drivers (Rising incidence of cancer, Increased investment and collaborations by key market players for the development of novel ADCs, Growing number of ADCs in clinical trials, Regulatory support for ADC development ), restraints ( High manufacturing costs, Side effects associated with ADCs, High attrition rate in product development), opportunities (Adoption of combination therapies, High growth in emerging economies, Emergence of advanced ADCs) and challenges (Technical complexities) are influencing the growth of antibody drug conjugates market.
• Product Development/Innovation: Detailed insights on newly launched products of the antibody drug conjugates market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the antibody drug conjugates market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the antibody drug conjugates market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India) and among others in the antibody drug conjugates market. 

Table of Contents

1            INTRODUCTION            37

1.1         STUDY OBJECTIVES      37

1.2         MARKET DEFINITION   37

1.2.1      INCLUSIONS AND EXCLUSIONS 38

1.3         MARKET SCOPE             38

1.3.1      MARKETS COVERED     38

1.3.2      YEARS CONSIDERED     39

1.3.3      CURRENCY CONSIDERED          39

1.4         RESEARCH LIMITATIONS           39

1.5         STAKEHOLDERS            40

1.6         RECESSION IMPACT      40

2            RESEARCH METHODOLOGY     41

2.1         RESEARCH DATA           41

FIGURE 1           RESEARCH DESIGN       41

2.1.1      SECONDARY DATA       41

2.1.2      PRIMARY DATA 42

FIGURE 2           ANTIBODY DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES        43

2.2         MARKET SIZE ESTIMATION       44

FIGURE 3           ANTIBODY DRUG CONJUGATES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS (2022)           44

FIGURE 4           MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)        44

FIGURE 5           ANTIBODY DRUG CONJUGATES MARKET: REVENUE SHARE ANALYSIS OF F-HOFFMAN LA ROCHE LTD.        45

2.2.1      PRIMARY INSIGHTS       46

FIGURE 6           MARKET VALIDATION FROM PRIMARY EXPERTS           46

2.2.2      SEGMENT ASSESSMENT METHODOLOGY          46

FIGURE 7           MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH       46

2.3         GROWTH RATE ASSUMPTIONS 47

FIGURE 8           ANTIBODY DRUG CONJUGATES MARKET: CAGR PROJECTION ANALYSIS          48

FIGURE 9           ANTIBODY DRUG CONJUGATES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES            48

2.4         MARKET BREAKDOWN AND DATA TRIANGULATION    49

FIGURE 10         DATA TRIANGULATION METHODOLOGY         49

2.5         STUDY ASSUMPTIONS  50

2.6         RISK ANALYSIS 50

2.7         RECESSION IMPACT ANALYSIS 50

TABLE 1             GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH)         51

TABLE 2             US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)  51

TABLE 3             US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)  51

3            EXECUTIVE SUMMARY 52

FIGURE 11         ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)             52

FIGURE 12         ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)     53

FIGURE 13         ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2023 VS. 2028 (USD MILLION)     53

FIGURE 14         ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2023 VS. 2028 (USD MILLION)     54

FIGURE 15         ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2023 VS. 2028 (USD MILLION)     55

FIGURE 16         GEOGRAPHICAL SNAPSHOT OF ANTIBODY DRUG CONJUGATES MARKET 56

4            PREMIUM INSIGHTS      57

4.1         ANTIBODY DRUG CONJUGATES MARKET OVERVIEW   57

FIGURE 17         RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 57

4.2         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE AND COUNTRY (2022)    58

FIGURE 18         BREAST CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET IN 2022      58

4.3         ANTIBODY DRUG CONJUGATES MARKET SHARE, BY PRODUCT, 2023 VS. 2028 58

FIGURE 19         KADCYLA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD       58

4.4         ANTIBODY DRUG CONJUGATES: GEOGRAPHIC GROWTH OPPORTUNITIES           59

FIGURE 20         ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH RATES FROM 2023 TO 2028         59

5            MARKET OVERVIEW     60

5.1         INTRODUCTION            60

5.2         MARKET DYNAMICS     60

FIGURE 21         ANTIBODY DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES       60

TABLE 4             ANTIBODY DRUG CONJUGATES MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES            61

5.2.1      DRIVERS            61

5.2.1.1   Rising incidence of cancer  61

TABLE 5            GLOBAL INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035     62

5.2.1.2   Increasing investments for ADC development             63

5.2.1.3   Growing number of ADCs in clinical trials     64

TABLE 6             ASSET RANKING FOR LEADING ADC DEVELOPERS (2019 VS. 2023)    64

5.2.1.4   Favorable regulatory support           66

5.2.2      RESTRAINTS     66

5.2.2.1   High manufacturing costs  66

5.2.2.2   Side effects associated with ADCs    67

5.2.2.3   High attrition rate in product development    67

TABLE 7             LIST OF DISCONTINUED ANTIBODY DRUG CONJUGATES (2020−2022)      67

5.2.3      OPPORTUNITIES           68

5.2.3.1   Adoption of combination therapies  68

5.2.3.2   High growth in emerging economies 69

5.2.3.3   Emergence of advanced ADCs         69

5.2.4      CHALLENGES   70

5.2.4.1   Technical complexities      70

5.3         PIPELINE ANALYSIS      70

FIGURE 22         ANTIBODY DRUG CONJUGATES MARKET: CLINICAL TRIALS              70

5.4         VALUE CHAIN ANALYSIS            71

FIGURE 23         ANTIBODY DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS          71

5.5         ECOSYSTEM ANALYSIS 74

5.5.1      ROLE IN ECOSYSTEM    74

5.6         TECHNOLOGY ANALYSIS           75

TABLE 8             LEADING TECHNOLOGICAL ADVANCEMENTS FOR ADC GENERATIONS 75

5.7         REGULATORY ASSESSMENT      77

5.7.1      FDA REGULATIONS ON ANTIBODY DRUG CONJUGATES            77

5.7.1.1   CLINICAL PHARMACOLOGY CONSIDERATIONS             77

5.7.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          78

TABLE 9             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         78

TABLE 10           EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         79

TABLE 11           ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         80

TABLE 12           LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         80

TABLE 13           MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         81

5.8         PORTER’S FIVE FORCES ANALYSIS         81

TABLE 14           ANTIBODY DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS         81

5.8.1      INTENSITY OF COMPETITIVE RIVALRY 81

5.8.2      BARGAINING POWER OF SUPPLIERS     82

5.8.3      BARGAINING POWER OF BUYERS           82

5.8.4      THREAT OF SUBSTITUTES         82

5.8.5      THREAT OF NEW ENTRANTS    82

5.9         PATENT ANALYSIS        83

5.9.1      LIST OF MAJOR PATENTS          84

5.10       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85

FIGURE 24         GROWING USE OF ACDS FOR ONCOLOGY AND OTHER CHRONIC DISEASES TO DRIVE MARKET             85

5.11       PRICING ANALYSIS        85

TABLE 15           ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY REGION            85

TABLE 16           ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY KEY PLAYERS   86

5.12       KEY CONFERENCES AND EVENTS          86

TABLE 17           ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF EVENTS AND CONFERENCES (2023−2024)         86

5.13       KEY STAKEHOLDERS AND BUYING CRITERIA    87

FIGURE 25         KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND INFLUENCE ON BUYING PROCESS         87

FIGURE 26         KEY BUYING CRITERIA FOR ADC PRODUCTS AMONG END USERS  87

6            ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT            89

6.1         INTRODUCTION            90

TABLE 18           ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)     90

6.2         KADCYLA          90

6.2.1      LAUNCH OF BIOSIMILARS TO DRIVE MARKET  90

TABLE 19           ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY REGION, 2021–2028 (USD MILLION)       91

TABLE 20           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION)            92

TABLE 21           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION)       92

TABLE 22           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION)       92

TABLE 23           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION)            93

6.3         ENHERTU          93

6.3.1      RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET  93

TABLE 24           ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2021–2028 (USD MILLION)       94

TABLE 25           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION)            94

TABLE 26           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION)      95

TABLE 27           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION)      95

TABLE 28           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION)            95

6.4         ADCETRIS         96

6.4.1      GROWING CASES OF HODGKIN LYMPHOMA TO DRIVE MARKET              96

TABLE 29           ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY REGION, 2021–2028 (USD MILLION)       97

TABLE 30           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION)           97

TABLE 31           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION)      98

TABLE 32           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION)      98

TABLE 33           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION)           98

6.5         PADCEV            99

6.5.1      RISING INCIDENCE OF UROTHELIAL CANCER TO DRIVE MARKET              99

TABLE 34           ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV MARKET, BY REGION, 2021–2028 (USD MILLION)            99

TABLE 35           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 100

TABLE 36           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION)         100

TABLE 37           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION)         100

TABLE 38           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 101

6.6         TRODELVY       101

6.6.1      INCREASING GOVERNMENT APPROVALS FOR BREAST CANCER TO DRIVE MARKET 101

TABLE 39           ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY MARKET, BY REGION, 2021–2028 (USD MILLION)            102

TABLE 40           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION)          102

TABLE 41           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION)    103

TABLE 42           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION)    103

TABLE 43           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION)          103

6.7         POLIVY 104

6.7.1      RISING PREVALENCE OF NON-HODGKIN LYMPHOMA TO PROPEL MARKET            104

TABLE 44           ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY MARKET, BY REGION, 2021–2028 (USD MILLION)            104

TABLE 45           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION)  105

TABLE 46           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION)           105

TABLE 47           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION)           105

TABLE 48           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION)  106

6.8         OTHER PRODUCTS       106

TABLE 49           ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION)        107

TABLE 50           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)         107

TABLE 51           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)    108

TABLE 52           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)    108

TABLE 53           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION)         108

7            ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE       109

7.1         INTRODUCTION            110

TABLE 54           ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)          110

7.2         CLEAVABLE LINKERS    110

7.2.1      HIGH COMPATIBILITY WITH BROAD RANGE OF DRUGS TO DRIVE MARKET            110

TABLE 55           ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY REGION, 2021–2028 (USD MILLION)             111

TABLE 56           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION)      111

TABLE 57           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 112

TABLE 58           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 112

TABLE 59           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION)      112

7.3         NON-CLEAVABLE LINKERS        113

7.3.1      LOW TOXICITY LEVELS TO SUPPORT MARKET GROWTH           113

TABLE 60           ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY REGION, 2021–2028 (USD MILLION)    113

TABLE 61           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION)              114

TABLE 62           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 114

TABLE 63           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION)    114

TABLE 64           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION)              115

8            ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE     116

8.1         INTRODUCTION            117

TABLE 65           ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)          117

8.2         HER2    117

8.2.1      RISING PREVALENCE OF BREAST CANCER TO DRIVE MARKET  117

TABLE 66           ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY REGION, 2021–2028 (USD MILLION)       118

TABLE 67           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION)      118

TABLE 68           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION)            119

TABLE 69           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION) 119

TABLE 70           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION)      119

8.3         CD22    120

8.3.1      INCREASING CASES OF B-CELL LYMPHOMAS TO DRIVE MARKET              120

TABLE 71           ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY REGION, 2021–2028 (USD MILLION)       120

TABLE 72           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION)      120

TABLE 73           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION)            121

TABLE 74           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION) 121

TABLE 75           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION)      121

8.4         CD30    122

8.4.1      INCREASING CLINICAL TRIALS FOR PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH    122

TABLE 76           ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY REGION, 2021–2028 (USD MILLION)       122

TABLE 77           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION)      123

TABLE 78           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION)            123

TABLE 79           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION) 123

TABLE 80           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION)      124

8.5         OTHER TARGET TYPES 124

TABLE 81           ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY REGION, 2021–2028 (USD MILLION)   124

TABLE 82           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION)  125

TABLE 83           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION)           125

TABLE 84           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION)           125

TABLE 85           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION)  126

9            ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE  127

9.1         INTRODUCTION            128

TABLE 86           ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)          128

9.2         MONOMETHYL AURISTATIN E 128

9.2.1      CYTOTOXIC PAYLOAD FOR ADC DEVELOPMENT TO DRIVE MARKET              128

TABLE 87           ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY REGION, 2021–2028 (USD MILLION)  129

TABLE 88           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION)              129

TABLE 89           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION)              130

TABLE 90           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION)              130

TABLE 91           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION)              130

9.3         CALICHEAMICIN            131

9.3.1      LAUNCH OF CALICHEAMICIN-BASED ADCS TO PROPEL MARKET              131

TABLE 92           ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY REGION, 2021–2028 (USD MILLION)            131

TABLE 93           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 131

TABLE 94           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION)        132

TABLE 95           ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION)        132

TABLE 96           LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 132

9.4         MAYTANSINOIDS          133

9.4.1      INNOVATIVE PRODUCT PIPELINE TO SUPPORT MARKET GROWTH              133

TABLE 97           ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY REGION, 2021–2028 (USD MILLION)           133

TABLE 98           NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION)             134

TABLE 99           EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION)       134

TABLE 100         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION)       134

TABLE 101         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION)             135

9.5         OTHER PAYLOAD TYPES           135

TABLE 102         ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2021–2028 (USD MILLION)            135

TABLE 103         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 136

TABLE 104         EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION)        136

TABLE 105         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION)        136

TABLE 106         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 137

10          ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE     138

10.1       INTRODUCTION            139

TABLE 107         ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)          139

10.2       BREAST CANCER            139

10.2.1    RISING CASES OF INFLAMMATORY BREAST CANCER TO DRIVE MARKET            139

TABLE 108         PROJECTION OF BREAST CANCER RATES           140

TABLE 109         ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION)             141

TABLE 110         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 141

TABLE 111         EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)        142

TABLE 112         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION)        142

TABLE 113         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 142

10.3       BLOOD CANCER            143

10.3.1    INCREASING FOCUS ON CLINICAL TRIALS FOR ADVANCED CONJUGATES TO PROPEL MARKET       143

TABLE 114         GLOBAL INCIDENCE OF BLOOD CANCER          143

TABLE 115         ESTIMATED NEW BLOOD CANCER CASES IN US (2023)  143

TABLE 116         ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY REGION, 2021–2028 (USD MILLION)             144

TABLE 117         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 144

TABLE 118         EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION)         145

TABLE 119         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION)         145

TABLE 120         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 145

10.4       OTHER DISEASE TYPES 146

TABLE 121         ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021–2028 (USD MILLION)   146

TABLE 122         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)  146

TABLE 123         EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)           147

TABLE 124         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)           147

TABLE 125         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION)  147

11          ANTIBODY DRUG CONJUGATES MARKET, BY REGION  148

11.1       INTRODUCTION            149

TABLE 126         ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2021–2028 (USD MILLION)     149

11.2       NORTH AMERICA          149

FIGURE 27         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT        150

TABLE 127         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)            150

TABLE 128         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)            151

TABLE 129         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)       151

TABLE 130         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)  152

TABLE 131         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)     152

TABLE 132         NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)     152

11.2.1    US         153

11.2.1.1 Rising regulatory approvals for ADCs to drive market  153

TABLE 133         US: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          153

TABLE 134        US: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)          154

TABLE 135         US: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             154

TABLE 136         US: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             154

TABLE 137         US: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             155

11.2.2    CANADA            155

11.2.2.1 High R&D investments for novel ADCs to propel market           155

TABLE 138         CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   156

TABLE 139         CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)            156

TABLE 140         CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        157

TABLE 141         CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           157

TABLE 142         CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           157

11.2.3    NORTH AMERICA: RECESSION IMPACT 158

11.3       EUROPE             158

TABLE 143         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    158

TABLE 144         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   159

TABLE 145         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             159

TABLE 146         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        159

TABLE 147         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           160

TABLE 148         EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           160

11.3.1    GERMANY         160

11.3.1.1 Increasing collaborations among market players for cancer therapeutics to propel market   160

TABLE 149         GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   161

TABLE 150         GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)            161

TABLE 151         GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        162

TABLE 152         GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           162

TABLE 153         GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           162

11.3.2    FRANCE             163

11.3.2.1 Growing demand for personalized therapeutics to drive market 163

TABLE 154         FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   163

TABLE 155         FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             164

TABLE 156         FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        164

TABLE 157         FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           164

TABLE 158         FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           165

11.3.3    UK         165

11.3.3.1 Increasing cancer burden to support market growth     165

TABLE 159         UK: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)          166

TABLE 160        UK: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)          166

TABLE 161         UK: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             166

TABLE 162         UK: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             167

TABLE 163         UK: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             167

11.3.4    ITALY   167

11.3.4.1 Rising industrial collaborations for ADC production to drive market        167

TABLE 164         ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   168

TABLE 165         ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             168

TABLE 166         ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             169

TABLE 167         ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             169

TABLE 168         ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             169

11.3.5    SPAIN   170

11.3.5.1 Rising focus on drug discovery to support market growth           170

TABLE 169         SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   170

TABLE 170         SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             171

TABLE 171         SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             171

TABLE 172         SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021–2028 (USD MILLION)          171

TABLE 173         SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             172

11.3.6    REST OF EUROPE           172

TABLE 174         REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)            173

TABLE 175         REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)       173

TABLE 176         REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)  174

TABLE 177         REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)     174

TABLE 178         REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)     174

11.3.7    EUROPE: RECESSION IMPACT   175

11.4       ASIA PACIFIC    175

FIGURE 28         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT        176

TABLE 179         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    177

TABLE 180         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   177

TABLE 181         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)            178

TABLE 182         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        178

TABLE 183         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           178

TABLE 184         ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           179

11.4.1    CHINA  179

11.4.1.1 Rising initiatives for advanced therapies to drive market            179

TABLE 185         CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   180

TABLE 186         CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             180

TABLE 187         CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        181

TABLE 188         CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             181

TABLE 189         CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             181

11.4.2    JAPAN  182

11.4.2.1 Favorable regulatory support to propel market             182

TABLE 190         JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   183

TABLE 191         JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             183

TABLE 192         JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             184

TABLE 193         JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             184

TABLE 194         JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             184

11.4.3    INDIA   185

11.4.3.1 Emergence of innovative biosimilars to drive market    185

TABLE 195         INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   185

TABLE 196         INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             186

TABLE 197         INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             186

TABLE 198         INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)             186

TABLE 199         INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             187

11.4.4    REST OF ASIA PACIFIC  187

TABLE 200         REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)        188

TABLE 201         REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)   188

TABLE 202         REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             189

TABLE 203         REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)  189

TABLE 204         REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)  189

11.4.5    ASIA PACIFIC: RECESSION IMPACT        190

11.5       LATIN AMERICA             190

TABLE 205         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    190

TABLE 206         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   191

TABLE 207         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)            191

TABLE 208         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        192

TABLE 209         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)           192

TABLE 210         LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)           192

11.5.1    BRAZIL 193

11.5.1.1 Regulatory approvals for breast cancer therapeutics to drive market         193

TABLE 211         BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)   193

TABLE 212         BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)             194

TABLE 213         BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)        194

TABLE 214         BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021–2028 (USD MILLION)          194

TABLE 215         BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)             195

11.5.2    REST OF LATIN AMERICA          195

TABLE 216         REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)        196

TABLE 217         REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)   196

TABLE 218         REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             197

TABLE 219         REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)  197

TABLE 220         REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)  197

11.5.3    LATIN AMERICA: RECESSION IMPACT   198

11.6       MIDDLE EAST & AFRICA             198

11.6.1    RISING PRODUCT LAUNCHES FOR CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH    198

TABLE 221         MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)        199

TABLE 222         MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION)   199

TABLE 223         MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION)             200

TABLE 224         MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION)  200

TABLE 225         MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)  200

11.7       MIDDLE EAST & AFRICA: RECESSION IMPACT   201

12          COMPETITIVE LANDSCAPE       202

12.1       INTRODUCTION            202

12.2       STRATEGIES ADOPTED BY KEY PLAYERS           202

TABLE 226         ANTIBODY DRUG CONJUGATES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS       202

12.3       REVENUE SHARE ANALYSIS       203

FIGURE 29         REVENUE SHARE ANALYSIS OF KEY PLAYERS (2019–2022)              204

12.4       MARKET SHARE ANALYSIS         204

FIGURE 30         MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)        204

TABLE 227         ANTIBODY DRUG CONJUGATES MARKET: INTENSITY OF COMPETITIVE RIVALRY             205

12.5       COMPANY EVALUATION MATRIX FOR KEY PLAYERS     206

FIGURE 31         ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (2022)    207

12.5.1    STARS  207

12.5.2    EMERGING LEADERS    207

12.5.3    PERVASIVE PLAYERS     208

12.5.4    PARTICIPANTS 208

12.6       COMPETITIVE BENCHMARKING OF 25 PLAYERS             208

12.6.1    PRODUCT FOOTPRINT OF 11 COMPANIES         208

TABLE 228         ANTIBODY DRUG CONJUGATES MARKET: COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS            208

TABLE 229         ANTIBODY DRUG CONJUGATES MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS            209

12.6.2    REGIONAL FOOTPRINT OF 26 COMPANIES        210

TABLE 230         ANTIBODY DRUG CONJUGATES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS            210

12.7       COMPANY EVALUATION MATRIX FOR STARTUPS/SMES             211

FIGURE 32         ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)       211

12.7.1    PROGRESSIVE COMPANIES       211

12.7.2    STARTING BLOCKS       212

12.7.3    RESPONSIVE COMPANIES          212

12.7.4    DYNAMIC COMPANIES 212

12.8       COMPETITIVE BENCHMARKING OF STARTUPS/SMES   212

TABLE 231         ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF KEY STARTUPS/SMES   212

TABLE 232         ANTIBODY DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES  215

12.9       COMPETITIVE SCENARIO AND TRENDS             216

12.9.1    PRODUCT LAUNCHES  216

TABLE 233         ANTIBODY DRUG CONJUGATES MARKET: PRODUCT LAUNCHES (JANUARY 2020–JUNE 2023) 216

12.9.2    DEALS  217

TABLE 234         ANTIBODY DRUG CONJUGATES MARKET: DEALS (JANUARY 2020−JUNE 2023)           217

13          COMPANY PROFILES    219

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

13.1       KEY PLAYERS   219

13.1.1    F. HOFFMANN-LA ROCHE LTD. 219

TABLE 235         F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW  219

FIGURE 33         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)              220

13.1.2    DAIICHI SANKYO COMPANY, LIMITED  222

TABLE 236         DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW              222

FIGURE 34         DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022)   223

13.1.3    SEAGEN INC.     228

TABLE 237         SEAGEN INC.: BUSINESS OVERVIEW       228

FIGURE 35         SEAGEN INC.: COMPANY SNAPSHOT (2022)       228

13.1.4    GILEAD SCIENCES, INC. 233

TABLE 238         GILEAD SCIENCES, INC.: BUSINESS OVERVIEW  233

FIGURE 36         GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022)  234

13.1.5    TAKEDA PHARMACEUTICAL COMPANY LIMITED          236

TABLE 239         TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW        236

FIGURE 37         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)          237

13.1.6    PFIZER INC.       239

TABLE 240         PFIZER INC.: BUSINESS OVERVIEW        239

FIGURE 38         PFIZER INC.: COMPANY SNAPSHOT (2022)         240

13.1.7    ASTELLAS PHARMA INC.            241

TABLE 241         ASTELLAS PHARMA INC.: BUSINESS OVERVIEW 241

FIGURE 39         ASTELLAS PHARMA INC: COMPANY SNAPSHOT (2022)  242

13.1.8    ASTRAZENECA 244

TABLE 242         ASTRAZENECA: BUSINESS OVERVIEW   244

FIGURE 40         ASTRAZENECA: COMPANY SNAPSHOT (2022)    245

13.1.9    ADC THERAPEUTICS SA             248

TABLE 243         ADC THERAPEUTICS SA: BUSINESS OVERVIEW 248

FIGURE 41         ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2022)  248

13.1.10  IMMUNOGEN, INC.        251

TABLE 244         IMMUNOGEN, INC.: BUSINESS OVERVIEW          251

FIGURE 42         IMMUNOGEN, INC.: COMPANY SNAPSHOT (2022)          251

13.1.11  ZYDUS GROUP 254

TABLE 245         ZYDUS GROUP: BUSINESS OVERVIEW   254

FIGURE 43         ZYDUS GROUP: COMPANY SNAPSHOT (2022)    254

13.2       OTHER PLAYERS           256

13.2.1    ABBVIE INC.      256

TABLE 246         ABBVIE INC.: BUSINESS OVERVIEW        256

13.2.2    AMBRX 258

TABLE 247         AMBRX: BUSINESS OVERVIEW   258

13.2.3    LEGOCHEM BIOSCIENCES, INC. 259

TABLE 248         LEGOCHEM BIOSCIENCES, INC.: BUSINESS OVERVIEW  259

13.2.4    BYONDIS           261

TABLE 249         BYONDIS: BUSINESS OVERVIEW             261

13.2.5    PROFOUNDBIO 262

TABLE 250         PROFOUNDBIO: BUSINESS OVERVIEW  262

13.2.6    REMEGEN         263

TABLE 251         REMEGEN: BUSINESS OVERVIEW           263

13.2.7    SUTRO BIOPHARMA, INC.          265

TABLE 252         SUTRO BIOPHARMA, INC.: BUSINESS OVERVIEW            265

13.2.8    LEPU BIOPHARMA CO., LTD.     267

TABLE 253         LEPU BIOPHARMA CO., LTD.: BUSINESS OVERVIEW       267

13.2.9    ZYMEWORKS INC.          268

TABLE 254         ZYMEWORKS INC.: BUSINESS OVERVIEW            268

13.2.10  MERSANA THERAPEUTICS         269

TABLE 255         MERSANA THERAPEUTICS: BUSINESS OVERVIEW           269

13.2.11  DUALITY BIOLOGICS    270

TABLE 256         DUALITY BIOLOGICS: BUSINESS OVERVIEW      270

13.2.12  LANOVA MEDICINES    271

TABLE 257         LANOVA MEDICINES: BUSINESS OVERVIEW       271

13.2.13  EXELIXIS, INC.  272

TABLE 258         EXELIXIS, INC.: BUSINESS OVERVIEW    272

13.2.14  BIONECURE THERAPEUTICS INC.          273

TABLE 259         BIONECURE THERAPEUTICS INC.: BUSINESS OVERVIEW              273

13.2.15  TRIPARTITE THERAPEUTICS, INC.         274

TABLE 260         TRIPARTITE THERAPEUTICS, INC.: BUSINESS OVERVIEW              274

*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

14          APPENDIX         275

14.1       DISCUSSION GUIDE      275

14.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             280

14.3       CUSTOMIZATION OPTIONS      282

14.4       RELATED REPORTS       282

14.5       AUTHOR DETAILS         283